Hyaluronic acid complexes / IBSA Derma
Profhilo 3.2% · 2 ml
High- and low-molecular-weight HA, local IFU scope and a critical reading of surveillance data.
Product Atlas · September 2026
The exact product comes first
Scope of this monograph#
Australian PROFHILO 3.2%, 2 ml. This monograph does not cover Profhilo Body or Structura.
Clinical statements below summarize the attached documents. They are not a complete prescribing label. Match the exact local product and current instructions to the clinical decision.
Composition & formulation#
The 2 ml presentation contains 32 mg high- plus 32 mg low-molecular-weight HA sodium salt in buffered physiological solution.[1]
How it works#
The manufacturer describes hydration and viscoelastic effects, with proposed tissue-remodeling activity. These mechanisms should be distinguished from measured patient outcomes.[1]
Indications & treatment areas#
The attached Australian IFU identifies malar-zygomatic and sub-malar facial contour and laxity treatment. Other areas and family variants need separate sources.[1]
Application considerations#
The IFU requires aseptic administration to healthy skin and prohibits mixing with other products. Use its local preparation and technique instructions.[1]
Contraindications & precautions#
The IFU prohibits concurrent laser resurfacing or medium-deep peeling and injection into inflamed areas. Check the complete current local contraindication list.[1]
Adverse effects & safety#
Pain, warmth, erythema, swelling and nodules are described; uncommon HA-related reports include necrosis, abscess, granuloma and hypersensitivity.[1]
Duration & follow-up#
The attached IFU describes an initial course and reassessment for maintenance. Its schedule is not evidence of a universal six-month effect.[1]
Distinctions that matter#
A low spontaneous-reporting proportion is not a true complication rate: exposure was estimated and passive surveillance misses unreported events.[3]
Four markets. Separate evidence.#
Documents below identify what has been attached in this research edition. “Source needed” means unverified here; it is not a statement that a product is unapproved.
A current, exact-product local label or regulatory record has not yet been reconciled in this edition. Regulatory status is unverified here.
Contribute a local source ↗A current, exact-product local label or regulatory record has not yet been reconciled in this edition. Regulatory status is unverified here.
Contribute a local source ↗A current, exact-product local label or regulatory record has not yet been reconciled in this edition. Regulatory status is unverified here.
Contribute a local source ↗Australian IFU and product-specific ARTG 387132 attached. Source retrieval does not imply that a 2022 IFU is the latest revision.[1][2]
Studies worth a closer look.#
A reporting rate is not a complication rate.
Use surveillance to investigate signals; use prospective data to estimate event frequency.
Follow the evidence.#
Retrieved 6 September 2026. A retrieval date does not establish that an older document is the latest approved revision. Studies marked “abstract” have not completed full-text appraisal.
- [1] PROFHILO Australian instructions for use ↗IBSA · label · Document accessed · Document: 11 January 2022 · Checked 2026-09-06
- [2] PROFHILO 3.2% 2 ml — ARTG 387132 ↗Therapeutic Goods Administration · regulator · Document accessed · Checked 2026-09-06
- [3] Salti et al. — HCC-HA post-marketing surveillance ↗Journal of Cosmetic Dermatology, 2025 · PMID 40654100 · study · Abstract accessed · Checked 2026-09-06
Cite this monograph#
Aesthetic Pass. Profhilo 3.2% · 2 ml. Product Atlas research edition 2026.09.06.1. https://aestheticpass.com/products/monographs/profhilo/